Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Interest & Investment Income (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Interest & Investment Income for 13 consecutive years, with $607000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 59.04% year-over-year to $607000.0, compared with a TTM value of $2.8 million through Dec 2025, down 62.53%, and an annual FY2025 reading of $2.8 million, down 62.53% over the prior year.
  • Interest & Investment Income was $607000.0 for Q4 2025 at Karyopharm Therapeutics, up from $553000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.8 million in Q1 2023 and bottomed at $55000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $1.2 million, with a median of $829000.0 recorded in 2022.
  • The sharpest move saw Interest & Investment Income plummeted 86.11% in 2021, then soared 3750.0% in 2023.
  • Year by year, Interest & Investment Income stood at $55000.0 in 2021, then soared by 2325.45% to $1.3 million in 2022, then surged by 88.91% to $2.5 million in 2023, then plummeted by 41.19% to $1.5 million in 2024, then tumbled by 59.04% to $607000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for KPTI at $607000.0 in Q4 2025, $553000.0 in Q3 2025, and $613000.0 in Q2 2025.